13D Filings
LENZ Therapeutics, Inc.
LENZ
Amendment
Ownership

7.50%

Total Shares

2,101,199

Issuer CIK

1815776

CUSIP

52635N103

Event Date

Jun 9, 2025

Accepted

Jun 12, 2025, 04:49 PM

Reporting Persons (9)
Joint Filing

This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.

NameType% of ClassAggregateSole VotingShared Voting
Versant Venture Capital VI, L.P.
Partnership
7.50%2,101,1992,101,1990
Versant Ventures VI GP, L.P.
Partnership
7.50%2,101,19902,101,199
Versant Ventures VI GP-GP, LLC
Other
7.50%2,101,19902,101,199
Versant Ventures VII GP-GP, LLC
Other
4.70%1,319,32301,319,323
Versant Venture Capital VII, L.P.
Partnership
4.70%1,319,3231,319,3230
Versant Ventures VII GP, L.P.
Partnership
4.70%1,319,32301,319,323
Versant Vantage II, L.P.
Partnership
3.00%842,162842,1620
Versant Vantage II GP, L.P.
Partnership
3.00%842,1620842,162
Versant Vantage II GP-GP, LLC
Other
3.00%842,1620842,162
Disclosure Items (2)

Security Title

Common Stock, par value $0.00001 per share

Issuer Name

LENZ Therapeutics, Inc.

Issuer Address

201 Lomas Santa Fe Dr., Solana Beach, CA, 92075

Percentage of Class

See Items 7-11 and 13 of the cover pages of this Amendment for each Reporting Person and the corresponding comments.

Number of Shares

See Items 7-11 and 13 of the cover pages of this Amendment for each Reporting Person and the corresponding comments.

Transactions

On June 10, 2025, Versant VII sold 350,000 shares of Common Stock at a price per share of $29.00 for aggregate proceeds of approximately $10,150,000.00